Related Experiment Video
Updated: Dec 18, 2025
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.4K
MANIFESTATIONS OF GLUCAGONOMA SYNDROME
AACE Clinical Case Reports
|June 12, 2020
Summary
This case study highlights glucagonoma syndrome in a young woman, detailing its rare symptoms like necrolytic migratory erythema and diabetes. Early diagnosis and surgical intervention are crucial for managing this rare pancreatic neuroendocrine tumor.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Glucagonoma is a rare pancreatic neuroendocrine tumor.
- Glucagonoma syndrome presents with a constellation of distinct clinical manifestations.
Observation:
- A 44-year-old female presented with symptoms including necrolytic migratory erythema, diabetes, depression, and deep venous thrombosis.
- Clinical findings included pancreatic and hepatic masses, elevated glucagon levels, and confirmed glucagonoma post-surgery.
Findings:
- The patient underwent pancreatectomy and hepatic lobectomy, followed by somatostatin analogue therapy.
- Treatment challenges include the disorder's rarity, limited evidence, late diagnosis, and potential for relapse.
Implications:
- This case contributes to understanding glucagonoma syndrome due to its low incidence and unique characteristics.
- Highlights the importance of multidisciplinary management for rare neuroendocrine tumors.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
703
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
703
01:24Glucagon-like Receptor Agonists
727
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
727
01:15Diabetes: Symptoms, Diagnosis, and Complications
1.9K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.9K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
611
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
611
01:27Glucose Transporters
27.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.0K
01:16Hormones Regulating Blood Glucose
6.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.0K